IRX Therapeutics (IRX)

Oncology Corporate Profile

HQ Location

140 West 57th Street, Suite 9C
New York, NY 10019

Company Description

IRX Therapeutics' mission is to discover and commercialize drugs that stimulate a coordinated TH1-specific cellular immune response to treat human diseases. This immune response is essential for the eradication of most viruses and tumors, and relies on the effective functioning of dendritic cells, macrophages, and T-cells

Website: http://www.irxtherapeutics.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
citoplurikin / IRX-2immunotherapy (stimulant of the TH1-specific cellular immune system)Head & Neck cancerII
IRX 4-6immunotherapyProstate cancerPreclinical
citoplurikin / IRX-2immunotherapy (stimulant of the TH1-specific cellular immune system)Various cancer typesPreclinical

View additional information on product candidates here »

Source


http://www.irxtherapeutics.com/

Recent News Headlines

IRX Therapeutics and ImmunID Announce Collaboration to Predict Response to IRX-2 Cancer Immunotherapy Using ImmunTraCkeR®

1/19/2016 12:27 pm

(IRX Therapeutics) Jan 19, 2016 - IRX Therapeutics, a clinical-stage bioresearch company developing cancer immunotherapies, and ImmunID, an immune molecular diagnostics and precision medicine company, today announced they have entered into a collaboration agreement for prediction of response to the IRX-2 immunotherapy candidate using the ImmunTraCkeR® assay.

VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer

4/27/2015 11:18 am

(Yahoo! Finance) Apr 27, 2015 - VentiRx Pharmaceuticals, Inc. announced today that the European Commission (EC), acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP), has granted orphan designation to motolimod (formally VTX-2337) as an orphan medicinal product for the treatment of ovarian cancer.

N-of-One to Provide Clinical Interpretation to the Diagnostic Laboratories Awarded the US Department of Veteran Affairs Contract for Clinical Cancer Genomic Testing in New England

4/7/2015 12:05 pm

(N-of-One) Apr 7, 2015 - N-of-One to enrich molecular profiling results with clinical and scientific evidence and targeted therapy options, initially focused on lung cancer patients, for the Veterans Integrated Service Network 1 (VISN 1) Precision Oncology Program.

VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer

9/2/2014 12:07 pm

(Puget Sound Business Journal) Sept 2, 2014 - VentiRx Pharmaceuticals, Inc. today announced that the FDA has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy.

VentiRx Pharmaceuticals Announces the Completion of Patient Enrollment in Randomized, Placebo-controlled Phase 2 Trial of VTX-2337 in Combination with Pegylated-Liposomal Doxorubicin in Platinum-resistant Ovarian Cancer

4/17/2014 11:54 am

(Reuters) Apr 17, 2014 - VentiRx Pharmaceuticals, Inc. today announced that enrollment has been completed in GOG-3003 (NCT01666444), a randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with Pegylated Liposomal Doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy.

New Qualitative Data Show 97.5% of Mastectomy Patients Who Underwent Tissue Expansion With AirXpanders' AeroForm(TM) Reported Only 'Mild-to-Moderate' or No Pain Post Procedure

10/15/2013 11:59 am

(StreetInsider) Oct 15, 2013 - AirXpanders Inc., a company developing novel technology for women who require tissue expansion for breast reconstruction following a mastectomy, today reported the full results of the PACE-2 (Patient Activated Controlled Expansion) trial of its AeroForm(TM) device.

VentiRx Pharmaceuticals Initiates the ACTIVE8 Phase 2 Clinical Trial Evaluating VTX-2337 in Combination with Cetuximab and Chemotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

7/2/2013 11:51 am

(Sacramento Bee) July 2, 2013 - VentiRx Pharmaceuticals, Inc. announced today the initiation of the ACTIVE8 clinical trial, a randomized, placebo-controlled, Phase 2 trial evaluating VTX-2337 in combination with a standard of care regimen, cetuximab, platinum and 5 Fluorouracil (5-FU), in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

VentiRx Pharmaceuticals Initiates Randomized, Placebo-controlled, Phase 2 Trial of VTX-2337 in Patients with Recurrent or Persistent Ovarian Cancer

10/22/2012 11:36 am

(Sacramento Bee) Oct 22, 2012 - VentiRx Pharmaceuticals, Inc. announced today the initiation of a randomized, placebo-controlled, Phase 2 trial evaluating VTX-2337 in combination with Doxil® (pegylated liposomal doxorubicin) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy.

Celgene Puts $35M into VentiRx, Gets Option to Buy Cancer Drugmaker

10/3/2012 12:21 pm

(Xconomy Seattle) Oct 3, 2012 - Celgene is putting some big money into a partnership with Seattle-based VentiRx Pharmaceuticals that aims to go a step further in developing cancer immunotherapies.

Io Therapeutics, Inc. Announces Initiation of Dosing in a Phase II Clinical Trial of IRX4204 in Patients With Advanced Prostate Cancer

10/7/2011 12:24 pm

(MarketWatch) Oct 6, 2011 - Io Therapeutics, Inc. announced today initiation of dosing in a phase II clinical trial with its experimental cancer therapeutic, IRX4204, in patients with advanced prostate cancer.

Immunovaccine and IRX Therapeutics Collaborate on Cancer Immunotherapies

10/5/2010 12:00 am

(MarketWatch) Oct 5, 2010 - Immunovaccine Inc. and IRX Therapeutics announced today that the two companies have entered into a preclinical research collaboration to evaluate the combination of IRX's primary cell-derived biologic, IRX-2, and DepoVax(TM) - based therapeutic cancer vaccines.

VentiRx Pharmaceuticals' Novel TLR8 Agonist, VTX-2337, Successfully Completes Phase 1 Clinical Trial in Oncology

10/5/2010 12:00 am

(Yahoo! Finance) Oct 4, 2010 - VentiRx Pharmaceuticals, Inc. announced today the successful completion of a Phase 1 clinical study for VTX-2337, its novel TLR8 agonist for oncology at the International Society for Biological Therapy of Cancer (ISBTC).

IRX Therapeutics Announces Cancer Vaccine Collaboration with Japan's National Cancer Research Center

4/29/2010 12:00 am

(New York dbusiness) April 29, 2010 - IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has established a strategic collaboration with Japan's National Cancer Research Center (NCRC) to evaluate next-generation peptide-based cancer vaccines.

Rubberduck Reveals Mobile TV Growth - Live TV Content and iPhone Applications Generates Surge in Viewers (PR Newswire)

2/15/2010 07:37 am

Rubberduck Media Lab, a Division of Aspiro and Europe's Leading